Αποτελέσματα αναζήτησης - Debashis Sarker

Περιορισμός αποτελεσμάτων
  1. 1
    Pharmacodynamic Biomarker Development for PI3K Pathway Therapeutics

    Pharmacodynamic Biomarker Development for PI3K Pathway Therapeutics από Debra H. Josephs, Debashis Sarker

    Έκδοση 2015
    Λήψη πλήρους κειμένου
    Revisão
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  2. 2
    Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer

    Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer από Debashis Sarker, Alison Reid, Timothy A. Yap, Johann S. de Bono

    Έκδοση 2009
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Revisão
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  3. 3
    Improving the outcome of patients with castration-resistant prostate cancer through rational drug development

    Improving the outcome of patients with castration-resistant prostate cancer through rational drug development από Gerhardt Attard, Debashis Sarker, Alison Reid, R. Molife, Chris Parker, Johann S. de Bono

    Έκδοση 2006
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Revisão
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  4. 4
    Effect of Patient Socioeconomic Status on Access to Early-Phase Cancer Trials

    Effect of Patient Socioeconomic Status on Access to Early-Phase Cancer Trials από Aisyah Mohd Noor, Debashis Sarker, Suzanne Vizor, Blair Kp McLennan, Sarah Hunter, Aneta Suder, Henrik Møller, James Spicer, Sophie Papa

    Έκδοση 2012
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  5. 5
    Chronic inflammation markers are associated with risk of pancreatic cancer in the Swedish AMORIS cohort study

    Chronic inflammation markers are associated with risk of pancreatic cancer in the Swedish AMORIS cohort study από Sam Sollie, Dominique S. Michaud, Debashis Sarker, Sophia N. Karagiannis, Debra H. Josephs, Niklas Hammar, Aida Santaolalla, Göran Walldius, Hans Garmo, Lars Holmberg, Ingmar Jungner, Mieke Van Hemelrijck

    Έκδοση 2019
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  6. 6
    First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer

    First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer από Christophe Massard, A. Ázaro, Jean‐Charles Soria, Ulrik Lassen, Christophe Le Tourneau, Debashis Sarker, Claire Smith, U. Ohnmacht, Gerard J. Oakley, Bharvin K.R. Patel, Eunice Yuen, Karim A. Benhadji, Jordi Rodón

    Έκδοση 2018
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  7. 7
    First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor

    First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor από Ruth Plummer, Divyanshu Dua, Nicola Cresti, Yvette Drew, Peter Stephens, Marie L. Foegh, Steen Knudsen, Perminder S. Sachdev, Bipin Mistry, Vaishali Dixit, Sharon McGonigle, Nancy Hall, Mark Matijevic, Shannon McGrath, Debashis Sarker

    Έκδοση 2020
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  8. 8
    A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer

    A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer από Rebecca Kristeleit, Ruth Plummer, Robert H. Jones, Louise Carter, Sarah P. Blagden, Debashis Sarker, Hendrik‐Tobias Arkenau, T.R. Jeffry Evans, Sarah Danson, Stefan N. Symeonides, Gareth J. Veal, Barbara Klencke, Mark Kowalski, Udai Banerji

    Έκδοση 2023
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  9. 9
    Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours

    Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours από Nicholas C. Turner, Sandra J. Strauss, Debashis Sarker, Roopinder Gillmore, Amy A. Kirkwood, A. Hackshaw, Anthie Papadopoulou, J. Bell, Irfan Kayani, Christos Toumpanakis, Federica Grillo, A Mayer, Daniel Hochhauser, Richard H. J. Beǵent, Martyn Caplin, Tim Meyer

    Έκδοση 2010
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  10. 10
    A Phase I Pharmacokinetic and Pharmacodynamic Study of TKI258, an Oral, Multitargeted Receptor Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors

    A Phase I Pharmacokinetic and Pharmacodynamic Study of TKI258, an Oral, Multitargeted Receptor Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors από Debashis Sarker, R. Molife, T. R. J. Evans, Maryon Hardie, Cheryl Marriott, Priska Butzberger-Zimmerli, Rosemary Morrison, Judith A. Fox, Carla Heise, Sharianne G. Louie, Natasha Aziz, F. Garzon, Glenn Michelson, Ian Judson, Dalal Jadayel, Edgar Braendle, Johann S. de Bono

    Έκδοση 2008
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  11. 11
    USP25 promotes pathological HIF-1-driven metabolic reprogramming and is a potential therapeutic target in pancreatic cancer

    USP25 promotes pathological HIF-1-driven metabolic reprogramming and is a potential therapeutic target in pancreatic cancer από Jessica K. Nelson, May Zaw Thin, Theodore Evan, Steven Howell, Mary Wu, Bruna Almeida, Nathalie Legrave, Duco S. Koenis, Gabriela Koifman, Yoichiro Sugimoto, Miriam Llorián Sopeña, James I. MacRae, Emma Nye, Michael Howell, Ambrosius P. Snijders, Andreas Prachalias, Yoh Zen, Debashis Sarker, Axel Behrens

    Έκδοση 2022
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  12. 12
    Quantification of Pancreatic Cancer Proteome and Phosphorylome: Indicates Molecular Events Likely Contributing to Cancer and Activity of Drug Targets

    Quantification of Pancreatic Cancer Proteome and Phosphorylome: Indicates Molecular Events Likely Contributing to Cancer and Activity of Drug Targets από D. Britton, Yoh Zen, Alberto Quaglia, Stefan Selzer, Vikram Mitra, Christopher Lößner, Stephan Jung, Gitte Böhm, Peter Schmid, Petra Prefot, Claudia Hoehle, Saša Končarević, Julia M.W. Gee, Robert I. Nicholson, Malcolm Ward, Leandro Castellano, Justin Stebbing, Hans Dieter Zucht, Debashis Sarker, Nigel Heaton, Ian Pike

    Έκδοση 2014
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  13. 13
    1913O Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC)

    1913O Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC) από Mimi I. Hu, Vivek Subbiah, Lori J. Wirth, M Schuler, Aaron S. Mansfield, Marcia S. Brose, Giuseppe Curigliano, Sophie Leboulleux, Viola W. Zhu, Bhumsuk Keam, Ignacio Matos, C-C. Lin, D.R. Adkins, Christina S. Baik, G. Lopes, Yann Godbert, Debashis Sarker, H. Zhang, Christopher D. Turner, Matthew Taylor

    Έκδοση 2020
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  14. 14
    The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer

    The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanc... από Udai Banerji, D. Ross Camidge, Henk M.W. Verheul, Roshan Agarwal, Debashis Sarker, Stan B. Kaye, Ingrid M.E. Desar, Johanna N.H. Timmer-Bonte, Sabine Eckhardt, Karl D. Lewis, Kathryn H. Brown, Mireille Cantarini, Clive Morris, Sarah M.A. George, Paul D. Smith, Carla M.L. van Herpen

    Έκδοση 2010
    Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  15. 15
    Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib

    Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib από Masatoshi Kudo, Richard S. Finn, Julien Edeline, Stéphane Cattan, Sadahisa Ogasawara, Daniel H. Palmer, Chris Verslype, Vittorina Zagonel, Lætitia Fartoux, Arndt Vogel, Debashis Sarker, Gontran Verset, Stephen L. Chan, Jennifer J. Knox, Bruno Daniele, Thomas Yau, Ellen B. Gurary, Abby B. Siegel, Anran Wang, Ann‐Lii Cheng, Andrew X. Zhu

    Έκδοση 2022
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  16. 16
    Study protocol: multi-centre, randomised controlled clinical trial exploring stromal targeting in locally advanced pancreatic cancer; STARPAC2

    Study protocol: multi-centre, randomised controlled clinical trial exploring stromal targeting in locally advanced pancreatic cancer; STARPAC2 από Hemant M. Kocher, Charlotte Ackerman, Garima Priyadarshini, Cheryl Lawrence, Nishtha Kotriwala, Ramona Georgescu, Rhiannon Roberts, Christine S. Hughes, Ahmet Imrali, Claude Chelala, Judith Dixon-Hughes, David K. Chang, Peter Sasieni, Pippa Corrie, Mairéad G. McNamara, Debashis Sarker, Fieke E. M. Froeling, Alan Christie, Roopinder Gillmore, Khurum Khan, David Propper

    Έκδοση 2025
    Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  17. 17
    Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer

    Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer από Hemant M. Kocher, Bristi Basu, Fieke E. M. Froeling, Debashis Sarker, Sarah Slater, Dominic Carlin, Nandita M. deSouza, Katja N. De Paepe, Michelle R. Goulart, Christine S. Hughes, Ahmet Imrali, Rhiannon Roberts, Maria Pawula, Richard Houghton, Cheryl Lawrence, Yathushan Yogeswaran, Kelly Mousa, Carike Coetzee, Peter Sasieni, Aaron Prendergast, David Propper

    Έκδοση 2020
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  18. 18
    First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors

    First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors από Debashis Sarker, Joo Ern Ang, Richard D. Baird, Rebecca Kristeleit, Krunal Shah, Víctor Moreno, Paul A. Clarke, Florence I. Raynaud, Gallia G. Levy, Joseph A. Ware, Kathryn Mazina, Ray Lin, Jenny Wu, Jill Fredrickson, Jill M. Spoerke, Mark R. Lackner, Yibing Yan, Lori S. Friedman, Stan B. Kaye, Mika K. Derynck, Paul Workman, Johann S. de Bono

    Έκδοση 2014
    Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  19. 19
    Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial

    Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial από Gontran Verset, Ivan Borbath, Mark Karwal, Chris Verslype, Hans Van Vlierberghe, Adel Kardosh, Vittorina Zagonel, Per Stål, Debashis Sarker, Daniel H. Palmer, Arndt Vogel, Julien Edeline, Stéphane Cattan, Masatoshi Kudo, Ann‐Lii Cheng, Sadahisa Ogasawara, Bruno Daniele, Stephen L. Chan, Jennifer J. Knox, Shukui Qin, Abby B. Siegel, Michael Chisamore, Ken Hatogai, Anran Wang, Richard S. Finn, Andrew X. Zhu

    Έκδοση 2022
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:
  20. 20
    CD73 controls Myosin II–driven invasion, metastasis, and immunosuppression in amoeboid pancreatic cancer cells

    CD73 controls Myosin II–driven invasion, metastasis, and immunosuppression in amoeboid pancreatic cancer cells από Rémi Samain, Óscar Maiques, Joanne Monger, Hoyin Lam, Juliana Candido, Samantha L. George, Nicola Ferrari, Leonie KohIhammer, Sophia Lunetto, A. Senra Varela, José L. Orgaz, F Vilardell, Jorge Juan Olsina Kissler, Xavier Matías‐Guiu, Debashis Sarker, Adrian Biddle, Frances R. Balkwill, Jim Eyles, Robert W. Wilkinson, Hemant M. Kocher, Fernando Calvo, Claire M. Wells, Victoria Sanz‐Moreno

    Έκδοση 2023
    Λήψη πλήρους κειμένου Λήψη πλήρους κειμένου
    Artigo
    Προσθήκη στα αγαπημένα
    Αποθηκεύτηκε σε:

Εργαλεία αναζήτησης: